中國批准另外兩種國產COVID-19疫苗作公共用途

Recently Yahoo News on-line reported the following:

China approves two more domestic COVID-19 vaccines for public use

Reuters Thu., February 25, 2021, 5:39 a.m.

BEIJING, Feb 25 (Reuters) - China's medical products regulator said on Thursday that it had approved two more COVID-19 vaccines for public use, raising the number of domestically produced vaccines that can be used in China to four.

The two newly cleared vaccines are made by CanSino Biologics Inc (CanSinoBIO) and Wuhan Institute of Biological Products, an affiliate of China National Pharmaceutical Group (Sinopharm).

They join a vaccine from Sinovac Biotech approved earlier this month, and another from Sinopharm's Beijing unit approved last year.

Prior to formal approval for wider public use by the National Medical Products Administration, millions of doses of the two Sinopharm vaccines and Sinovac shot had been administered in China's vaccination program. The program targets select groups of people facing a higher risk of infection.

CanSinoBIO's vaccine has been given the green light for use by military personnel.

So far, China has not approved COVID-19 vaccines developed by Western drug makers.

The four approved Chinese vaccines can be stored at normal freezer temperatures - a potential selling point in less affluent countries that might have difficulty deploying vaccines from Pfizer and Moderna that require much colder temperatures for longer-term storage.

The three companies have all secured supply deals overseas, and China has donated doses made by Sinopharm's Beijing unit to numerous countries. China is exporting vaccines to 27 countries and providing free doses to 53 countries, a foreign ministry spokesman said on Tuesday.

Interim results from large late-stage trials showed the vaccine from Sinopharm's Wuhan unit was 71.25% effective against the disease caused by the new coronavirus, lower than the 79.34% efficacy reading of the shot from its Beijing unit using similar technology, according to company statements.

Sinovac said a Brazil-based Phase III clinical trial showed its vaccine was 50.65% effective against COVID-19, while a test on human in Turkey yielded a 91.25% efficacy rate, based on preliminary results.

CanSinoBIO said its vaccine was 68.83% effective at preventing symptomatic COVID-19 disease two weeks after a single-dose vaccination, citing interim data, while the rate fell to 65.28% four weeks after one shot.

Detailed data interpreting these headline figures are yet to be made available to the public.

Translation

(路透社) 北京2月25日電 - 中國醫療產品監管機構週四表示，已批准另外兩種作公共使用的COVID-19疫苗，從而使可在中國使用的國產疫苗數量增加到四種。

這兩種新允許的疫苗, 一是由康希诺生物(CanSino Biologics Inc.)（CanSinoBIO）生產, 另一是中國國家醫藥集團（Sinopharm）的子公司, 武漢生物製品研究所生產。

他們加入了本月初獲得批准的科興 (Sinovac Biotech) 的疫苗，及去年獲得批准的國藥集團北京分公司的一種疫苗的提供行列。

在獲得國家醫療產品管理局的正式批准以供更廣泛的公眾使用之前，中國的疫​​苗接種計劃已用了數百萬劑國藥疫苗和科興注射劑進行了注射。該計劃的目標人群是面臨較高感染風險的特定群體。

康希诺生物的疫苗已獲得批准供軍事人員使用。

迄今為止，中國尚未批准西方製藥商開發的COVID-19疫苗。

四種已獲批准的中國疫苗可以在正常的冰箱溫度下儲存 - 在較不富裕的國家中可能是一個賣點，這些國家可能難以依從輝瑞和Moderna部署疫苗的要求，這些疫苗需要較低的溫度才能長期保存。

三家公司都已取得了在海外的供應交易合約，中國已將國藥控股北京分公司製造的劑量捐贈給了許多國家。外交部發言人周二表示，中國正在向27個國家出口疫苗，並向53個國家提供免費疫苗。

公司聲明稱，大型後期試驗的中期結果顯示，國藥集團武漢分公司的疫苗對新型冠狀病毒引起的疾病的有效率為71.25％，低於北京分公司使用類似技術的注射疫苗的79.34％功效。 。

科興表示，一項基於巴西的第三期臨床試驗顯示，其疫苗對COVID-19的有效率為50.65％，而根據初步結果，在土耳其進行的人體試驗產生了91.25％的有效率。

康希诺生物表示，根據臨時數據，單劑量疫苗接種後兩週，該疫苗可有以效預防有症狀的COVID-19疾病，其有效率為68.83％，而一次注射後四周，有效率降至65.28％。

解釋這些重要數字的詳細數據尚未向公眾公開。

              So, up to now, China has approved 4 vaccines. They include the newly permitted vaccines made by CanSino Biologics Inc. (CanSinoBIO), two types of vaccines from the National Pharmaceutical Group (Sinopharm) made respectively in Beijing or Wuhan, and lastly the vaccine from Sinovac Biotech.